Pulse Biosciences initiates thyroid cancer study with MD Anderson; IDE approved

PULSE BIOSCIENCES, INC.

FDA-approved IDE for first-in-human feasibility study of nPulse Vybrance system in papillary thyroid microcarcinoma.
Study to commence early 2026, enroll 30 subjects at two sites, led by Dr. Victoria Banuchi at MD Anderson.
Preclinical studies ongoing for anaplastic thyroid carcinoma, a rare cancer with <5% five-year survival rate.
nPulse technology uses nonthermal nsPFA to limit scarring and damage to surrounding structures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.